Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06480565 · ClinicalTrials.gov registry record · Phase 1

A Phase 1/2 Trial of ADI-270 in ccRCC

A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Adicet Therapeutics.

Active
Registry status
Phase 1
Development phase
60
Enrollment target
1
Study location

NCT06480565: Active Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Adicet Therapeutics.

NCT06480565 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that is active but no longer recruiting, run by Adicet Therapeutics. The registered enrollment target is 60 participants, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06480565, a Phase 1 study of Clear Cell Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Adicet Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

Primary Outcome

This primary endpoint will be used to determine the Maximum Tolerated Dose (MTD) or Maximum Assessed dose (MAD)

Conditions Studied

Clear Cell Renal Cell Carcinoma

Interventions

  • DRUG Cyclophosphamide
  • DRUG Fludarabine
  • DRUG ADI-270

Study Locations (1)

California

  • Adicet Clinical Trials - Redwood City

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2024-12-12
Est. Completion 2027-06
Phase Phase 1
Adicet Therapeutics

3 total trials

What the registry record for NCT06480565 still lists

NCT06480565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 202-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.

NCT06480565 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06480565 about?

NCT06480565 is a clinical study titled "A Phase 1/2 Trial of ADI-270 in ccRCC". This is a Phase 1/2 multicenter, open-label, dose escalation, and dose expansion study of ADI-270 - an Engineered gamma-delta Chimeric Receptor \[CAR\] Vδ1 T Cell product Targeting CD70 - in patients with R/R ccRCC.

What is the current status of trial NCT06480565?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2024-12-12. Estimated completion is 2027-06.

What conditions does trial NCT06480565 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.

What interventions are being tested in trial NCT06480565?

The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), ADI-270 (DRUG).

Who is sponsoring clinical trial NCT06480565?

This trial is sponsored by Adicet Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06480565 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06480565's enrollment target sits among peer trials

60 29th of 45 higher than 16 of 45 other Clear Cell Renal Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Clear Cell Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06480565, the US trial registry maintained by the National Library of Medicine. NCT06480565 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.